[(212)Pb]Pb-eSOMA-01: A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors

Peptide receptor radionuclide therapy (PRRT) has been applied to the treatment of neuroendocrine tumors (NETs) for over two decades. However, improvement is still needed, and targeted alpha therapy (TAT) with alpha emitters such as lead-212 ((212)Pb) represents a promising avenue. A series of ligand...

Descripción completa

Detalles Bibliográficos
Autores principales: Chapeau, Dylan, Koustoulidou, Sofia, Handula, Maryana, Beekman, Savanne, de Ridder, Corrina, Stuurman, Debra, de Blois, Erik, Buchatskaya, Yulia, van der Schilden, Karlijn, de Jong, Marion, Konijnenberg, Mark W., Seimbille, Yann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384862/
https://www.ncbi.nlm.nih.gov/pubmed/37513897
http://dx.doi.org/10.3390/ph16070985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384862/
https://www.ncbi.nlm.nih.gov/pubmed/37513897
http://dx.doi.org/10.3390/ph16070985

Ejemplares similares